Autifony Therapeutics Limited has announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results